Dermatomyositis ILD full details for md exams 15marks answer from fishman and murray and ats and ers guidelines just from these only

Reading File

Finding Sources

Reading File

Loading Image

I now have all the content needed for a comprehensive 15-mark MD exam answer. Let me compile this into a structured, detailed response.

Dermatomyositis - Interstitial Lung Disease (ILD)

15-Mark MD Examination Answer

Sources: Fishman's Pulmonary Diseases and Disorders (Chapter 58) | Murray & Nadel's Textbook of Respiratory Medicine (Chapter 92)

1. INTRODUCTION AND OVERVIEW

Dermatomyositis (DM) is a systemic autoimmune inflammatory myopathy distinguished from polymyositis (PM) by the presence of prominent skin involvement - the heliotropic rash (violaceous/purplish periorbital discoloration) and Gottron papules (erythematous scaly eruptions over the extensor surfaces of the finger joints). The disease belongs to the broader category of idiopathic inflammatory myopathies (IIMs).

Pulmonary complications are common and important causes of morbidity and mortality in DM. Pulmonary involvement has been reported in up to 40-45% of cases. In contrast to other connective tissue diseases (CTDs), in PM/DM, primary involvement of the airways and pleura does not routinely occur - the predominant pulmonary manifestation is parenchymal ILD.

Fishman's Pulmonary Diseases and Disorders, p. 1031
Murray & Nadel's Textbook of Respiratory Medicine, p. 2098

2. EPIDEMIOLOGY

Prevalence of ILD in PM/DM: 5% to 30% in most Western series; approaches 40-80% in Japanese populations in some series
When screened with HRCT, incidence approaches 78% within 3 years of diagnosis (Fishman's)
In larger series using BAL and HRCT for screening, documented incidence of diffuse lung disease can be up to 64% (Murray & Nadel)
ILD in DM is 3 to 5 times more common in women than men
Most commonly presents in the fifth decade
Bimodal age distribution of the underlying myopathies: childhood peak and fourth to fifth decade peak
HLA associations: HLA-B8/DR3, HLA-B14, HLA-B40 in DM; presence of diffuse lung disease has been associated with two specific HLA haplotypes
Inflammatory myopathies are relatively rare: 2 to 10 per 100,000 population, female-to-male ratio 2.5:1
Fishman's, p. 1031; Murray & Nadel, p. 2099

3. DIAGNOSTIC CRITERIA (Bohan and Peter Criteria)

Criterion	Feature
1	Symmetrical proximal muscle weakness
2	Muscle biopsy specimen showing myositis
3	Elevation of serum skeletal muscle enzymes
4	Characteristic electromyographic pattern of myositis
5	Typical rash of DM (heliotrope rash / Gottron papules)

For DM: Rash + any 3 of first 4 = definite; rash + 2 of first 4 = probable; rash + 1 of first 4 = possible.

Lung Manifestations listed by Murray & Nadel (Table 92.5):

Interstitial pulmonary fibrosis
Acute pneumonitis (with diffuse alveolar damage)
Organizing pneumonia
Aspiration pneumonia
Pulmonary vasculitis and alveolar hemorrhage
Respiratory muscle weakness

4. PULMONARY MANIFESTATIONS - FULL SPECTRUM

4.1 Interstitial Lung Disease (ILD) - The Most Important

Histological Patterns (in order of frequency):

Pattern	Notes
NSIP (Nonspecific Interstitial Pneumonia)	Most common overall; 82% in biopsied patients in one large series (Douglas et al.); more cellular, more responsive to treatment
OP (Organizing Pneumonia)	Often admixed with NSIP; major component early; corticosteroid-responsive
UIP (Usual Interstitial Pneumonia)	Previously thought predominant; less common with revised classifications
DAD (Diffuse Alveolar Damage)	Acute presentation; associated with poorer prognosis; often refractory to treatment
DAH (Diffuse Alveolar Hemorrhage)	Due to pulmonary capillaritis; less common

Key point from Fishman's: While UIP was previously reported as predominant, NSIP with organizing pneumonia now appears most common based on the revised IIP classification system.

Temporal relationship: ILD may precede, appear simultaneously with, or follow the muscle/skin manifestations. In fact, ILD may precede joint and muscle disease by several months to years.

Important negative correlations (Fishman's): There is NO relationship between ILD and:

Extent of muscle or skin disease
Level of creatine phosphokinase (CPK) elevation
Presence of serum rheumatoid factor or antinuclear antibodies
Fishman's, p. 1031; Murray & Nadel, p. 2099

4.2 Aspiration Pneumonia

Occurs in 10-20% of patients with PM/DM (Murray & Nadel: up to 20%)
Mechanism: Inflammatory myositis affecting the striated muscle of the hypopharynx and upper one-third of the esophagus → loss of normal swallowing function → failure to protect the airway
Almost half of these patients complain of dysphagia
More likely in patients with extensive skin or muscle involvement

4.3 Respiratory Muscle Dysfunction

Hypercapnic respiratory failure requiring assisted ventilation occurs in approximately 5% of patients (Fishman's) or up to 25% (Murray & Nadel) due to extensive myositis involving respiratory muscles and diaphragm
With less extensive involvement: reduction in cough generation → hypostatic pneumonia, atelectasis from mucus plugging
Weakness causes a restrictive physiologic defect with tachypnea and dyspnea despite normal diffusing capacity and normoxia
Best demonstrated by measurement of maximal pressures generated during both phases of the respiratory cycle - useful for monitoring disease course and treatment response
Bilateral diaphragmatic paralysis has been reported

4.4 Pulmonary Arterial Hypertension

WHO Group I PAH has been reported but is uncommon
Most often in cases with suspected crossover with scleroderma
Patients present with dyspnea and fatigue, normal chest radiographs except for pulmonary arterial enlargement and isolated reduction in DLCO

5. AUTOANTIBODIES AND THE ANTISYNTHETASE SYNDROME

This is the most examinable section and directly links serology to pulmonary manifestations.

Anti-Jo-1 (anti-histidyl tRNA synthetase):

Present in 25% of all patients with PM/DM
Present in 50-100% of patients with PM/DM + ILD
Present in only 5-13% of patients without ILD
Most common of the antisynthetase antibodies

Other antisynthetase antibodies: PL-12, PL-7, EJ, OJ, Ku - all associated with ILD

Anti-MDA5 (Melanoma Differentiation-Associated gene 5):

Associated with rapidly progressive ILD
Often amyopathic DM (rash without significant muscle involvement)
Particularly relevant given its association with acute, treatment-refractory ILD

The Antisynthetase Syndrome (Murray & Nadel Table 92.6):

A patient must have a positive anti-tRNA antibody PLUS one or more of:

Myositis (by Bohan and Peter criteria)
ILD (by ATS criteria)
Arthritis
Unexplained, persistent fever
Raynaud phenomenon
Distal digital fissuring ("mechanic's hands")

Key clinical pearl from Murray & Nadel: Low creatine kinase levels have been associated with more rapidly progressive diffuse lung disease - counterintuitive but important. Several studies report NO association between CK levels and respiratory disease severity.

Fishman's, p. 1031; Murray & Nadel, p. 2100

6. CLINICAL FEATURES OF DM-ILD

Symptoms:

Dyspnea and nonproductive cough are the most common presenting symptoms
Breathlessness on exertion without wheeze
If myopathy is severe: orthopnea may be striking
Hemoptysis if capillaritis is present
Pleural disease is uncommon
No correlation between severity of pulmonary involvement and systemic musculoskeletal manifestations
Rarely, patients present acutely with or progress to acute respiratory failure

Timing: Pulmonary involvement can develop before the systemic disease, at any time during the disease course, or after established muscle/skin disease.

7. IMAGING

Chest Radiograph

Fig: Organizing pneumonia in PM/DM: diffuse patchy alveolar infiltrates (Fishman's, Fig. 58-20)

Chronic ILD: bibasilar reticulonodular infiltrates; with progression, reduced lung volume, honeycomb lung
Acute pneumonitis (DAD): diffuse ground-glass opacification
Alveolar hemorrhage: areas of consolidation
With disease progression: reduction of lung volumes, development of radiographic honeycomb lung and pulmonary hypertension

HRCT

Organizing pneumonia in PM - CT before and after treatment showing regression of consolidation with residual traction bronchiectasis

Fig: (A) Dense posterior consolidation of organizing pneumonia in PM; (B) Post-treatment: regression of consolidation with residual linear opacities and traction bronchiectasis (Murray & Nadel, Fig. 92.5)

HRCT is more sensitive and specific than chest radiography. CT findings include:

Thickened interlobular septa
Linear opacities
Ground-glass opacification (prominent early feature)
Patchy consolidation
Peripheral reticular pattern - combination of consolidation with peripheral reticular pattern is highly characteristic
Traction bronchiectasis and honeycombing (less common, seen with fibrotic disease)
The consolidation may evolve into a reticular pattern over time
HRCT screening increases documented ILD incidence to approximately 78% within 3 years

NSIP on HRCT: Bilateral ground-glass opacity with or without reticulation, basal predominant, subpleural sparing (in some cases) OP on HRCT: Dense posterior lower-lobe consolidation, most prominent posteriorly

Fishman's, p. 1031; Murray & Nadel, p. 2099

8. PULMONARY FUNCTION TESTS

Restrictive ventilatory defect: Reduced TLC, FVC, FEV1 with preserved FEV1/FVC ratio
Reduced DLCO - severe reduction associated with increased mortality
With recent hemorrhage or marked myopathy: disproportionate preservation of DLCO (because hemorrhage artificially elevates CO uptake)
Acute hemorrhage can present in context of previous chronic disease; DLCO may be normal or subnormal but elevated from a previously lower level
Respiratory muscle weakness alone can cause restrictive defect with normal diffusing capacity and normoxia (distinguishes it from parenchymal ILD)

9. BRONCHOALVEOLAR LAVAGE (BAL)

BAL lymphocytosis AND neutrophilia have been described in PM/DM-associated ILD
Neutrophilia on BAL is associated with clinical deterioration (Murray & Nadel)
BAL helps exclude infectious etiologies before initiating immunosuppression

10. LABORATORY INVESTIGATIONS

Investigation	Finding
Serum CK	Elevated in active myositis; NOT correlated with ILD severity
Anti-Jo-1	Positive in 50-100% of DM/ILD cases; indicates antisynthetase syndrome
Anti-MDA5	Rapidly progressive ILD, often amyopathic DM
Anti-PL-12, PL-7, EJ, OJ	Other antisynthetase antibodies
ANA	May be positive
RF	Present in some; NOT related to ILD
BAL	Lymphocytosis ± neutrophilia

Note from Murray & Nadel: Screening for occult malignancy is recommended in DM/PM (mammography, abdominal CT, pelvic ultrasonography, tumor markers, PET in some settings) because DM is a well-recognized paraneoplastic phenomenon.

11. ACUTE vs. SUBACUTE vs. CHRONIC ILD PRESENTATIONS

Presentation	Underlying Lesion	Prognosis	Response to Treatment
Chronic	NSIP (cellular or fibrotic)	Better for cellular NSIP	Good - steroid responsive
Subacute	OP ± NSIP	Intermediate	Good - corticosteroid responsive
Acute/Rapidly Progressive	DAD	Poor	Usually refractory - "recovery is unusual"
With hemoptysis	Pulmonary capillaritis/DAH	Intermediate	Corticosteroids + cyclophosphamide

Fishman's, p. 1031-1032

12. TREATMENT

First-Line

Corticosteroids are the preferred initial therapy:

Oral prednisolone 0.75-1 mg/kg/day for stable/subacute disease
IV corticosteroids required for severe or rapidly progressive disease

Second-Line (Steroid-Resistant or Steroid-Sparing)

The following have been used with efficacy per both textbooks:

Agent	Notes
Cyclophosphamide	For DAH (with corticosteroids), severe/refractory disease
Cyclosporin A	Calcineurin inhibitor; used in steroid-resistant cases
Tacrolimus	Calcineurin inhibitor; multiple reports of efficacy in PM/DM-ILD
Azathioprine	Steroid-sparing agent
Mycophenolate mofetil (MMF)	Steroid-sparing; used with increasing frequency
IV Immunoglobulin (IVIG)	Considered in refractory cases
Rituximab	Promising for antisynthetase syndrome; retrospective studies show CTD-ILD stabilization; myositis-associated ILD may represent the subgroup with greatest response to rituximab

Key points:

Response to treatment depends on underlying histology - more cellular disease is more responsive (Fishman's)
NSIP/OP patterns: corticosteroid responsive
DAD pattern: poor response; "recovery is unusual despite aggressive anti-inflammatory and immunosuppressive therapy" (Fishman's)
DAH due to capillaritis: immunosuppression with corticosteroids + cyclophosphamide is utilized and has been efficacious
In refractory cases: IVIG should be considered; rituximab is promising, especially for antisynthetase syndrome including life-threatening disease refractory to other immunomodulatory therapies
Fishman's, p. 1032; Murray & Nadel, p. 2100-2101

13. PROGNOSIS

ILD is a serious complication associated with increased mortality
DM/PM are the most frequent cause of death from pulmonary complications (~45% of patients affected)
Severe reduction in DLCO is associated with increased mortality
Clinical course is heterogeneous and depends on histologic pattern
Rapidly progressive ILD (especially with anti-MDA5 antibodies or DAD pattern) carries the worst prognosis
BAL neutrophilia is associated with clinical deterioration
DM/PM are well-recognized paraneoplastic phenomena - underlying malignancy must be excluded

14. INTERSTITIAL PNEUMONIA WITH AUTOIMMUNE FEATURES (IPAF)

A proportion of patients with IIP have autoimmune signs/symptoms but fail to meet established CTD criteria. The ERS/ATS Task Force established the IPAF concept with three domains:

Clinical domain - specific extrathoracic features
Serologic domain - specific autoantibodies (including antisynthetase antibodies)
Morphologic domain - radiographic, pathologic, and physiologic features

In most CTDs other than RA, NSIP is the most common radiographic and pathologic pattern. UIP pattern is more common in IPAF (65%) compared to NSIP. Acute exacerbations may be less frequent in IPAF and more responsive to anti-inflammatory therapy.

Fishman's, p. 1033-1034

15. SUMMARY TABLE FOR QUICK REVISION

Feature	Key Detail
ILD prevalence	5-30% (West); 40-80% (Japan); up to 78% on HRCT screening
Predominant histology	NSIP > OP > UIP > DAD
Key autoantibody	Anti-Jo-1 (50-100% of DM+ILD cases)
Rapidly progressive ILD marker	Anti-MDA5
Antisynthetase syndrome	Anti-tRNA Ab + myositis/ILD/arthritis/Raynaud/mechanic's hands/fever
ILD vs muscle disease correlation	None - ILD may precede muscle disease
CK and ILD	No correlation; low CK = more rapidly progressive ILD
Imaging hallmark	Peripheral reticular + consolidation (HRCT); bibasilar reticulonodular (CXR)
BAL	Lymphocytosis + neutrophilia; neutrophilia = clinical deterioration
PFT	Restrictive + reduced DLCO; severe DLCO reduction = increased mortality
First-line treatment	Prednisolone 0.75-1 mg/kg/day (oral) or IV for severe/RP-ILD
Best response to treatment	Cellular NSIP, OP patterns
Worst prognosis pattern	DAD - "recovery is unusual"
DAH treatment	Corticosteroids + cyclophosphamide
Refractory ILD	Rituximab, IVIG
Malignancy screening	Mandatory - DM is a paraneoplastic phenomenon

Sources:

Fishman's Pulmonary Diseases and Disorders, 2-Volume Set, Chapter 58: Pulmonary Manifestations of Collagen Vascular Diseases (pp. 1029-1034)
Murray & Nadel's Textbook of Respiratory Medicine, 2-Volume Set, Chapter 92: Pulmonary Manifestations of Connective Tissue Diseases (pp. 2098-2101, Table 92.5, Table 92.6)

This is a shared conversation. Sign in to Orris to start your own chat.